1. Бунятян Н.Д., Васильев А.Н., Гавришина Е.В. и др. Орфанные лекарственные препараты: США, Европейский союз и Россия // Ремедиум. 2013. (11). 47–52.
2. Матулевич С.А., Голихина Т.А., Денисенкова Е.В. и др. Федеральные клинические рекомендации по диагностике и лечению фенилкетонурии. М., 2013. 43 c.
3. Мировая статистика здравоохранения, медико-санитарные данные из государств-членов ВОЗ, отчетные материалы ВОЗ, 2011-2013: URL: http://www.who.int/gho/publications/world_health_statistics/ru/.
4. Муковисцидоз, современные достижения и актуальные проблемы: Данные Медико-генетического научного центра РАМН, с использованием материалов ВОЗ, Международной организации помощи больным муковисцидозом, Европейской ассоциации муковисцидоза и Российского центра муковисцидоза и научно-клинического отдела муковисцидоза МГНЦ РАМН. М., 2011. 92 с.
5. Ягудина Р.И., Зеленова Е.Г., Королева Н.И. Орфанные болезни. Проблемы и перспективы создания средств терапии // Нов. аптека. 2012. (9). 15–23.
6. Cassidy S.B., Driscoll D.J. Prader-Willi syndrome // Eur. J. Hum. Genet. 2009. 17. 3–13.
7. Celgene. Thalomid®: System for Thalomide Education and Prescribing Safety. http://www. thalomid.com/steps_program.aspx (accessed August 9, 2010).
8. Checking-in and electronic filing of documentation for orphan medicinal product designation (SOP/H/3047) http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_-_SOP/2009/09/WC500002945.pdf
9. Сommission Regulation (EC) N 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’ // Official J. Eur. Union. 2000. 103. (5). 1-4.0
10. Communication from the Commission on Regulation (EC) N 141/2000 of the European Parliament and of the Council on orphan medicinal products // Official J. Eur. Union. 2003. 178. (2). 1–7.
11. De Vrueh R.L.A. Why R&D into Rare Diseases Matter // Rare Diseases in the Age of Health 2.0, Communications in Medical and Care Compunetics 4. Berlin, Heidelberg: Springer-Verlag, 2014. 3–20.
12. Dietz H.C. New therapeutic approaches for Mendelian disorders // N. Engl. J. Med. 2010. 363. 852–863.
13. Dionisi Vici C., Rizzo C., Burlina A.B. et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey // J. Pediatr. 2002. 140. 321–327.
14. European Medicines Agency, EMA, 2011–2013. URL: http://www.ema/europa.eu/ema/.
15. Imel E.A., DiMeglio L.A., Hui S.L. et al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations // J. Clin. Endocrinol. Metab. 2010. 95. (4). 1846–1850.
16. Joppi R., Bertele V., Garattini S. Orphan drug development is not taking off // Br. J. Clin. Pharmacol. 2009. 67. (5). 494–502.
17 Joppi R., Bertele V., Garattini S. Orphan drug development is progressing too slowly // Br. J. Clin. Pharmacol. 2006. 61(3). 355–360.
18. Kataria M.K., Garg M., Anand V. et al. An insight on regulations governing orphan diseases and drugs // Res. J. Pharm. Biol. Chem. Sci. 2011. 2. (3). 373–385.
19. Maron B.J., Estes N.A.M. Commotio cordis // N. Engl. J. Med. 2010. 62. (10). 917–927.
20. Mitsumoto J., Dorsey E.R., Beck C.A. et al. Pivotal studies of orphan drugs approved for neurological diseases // Ann. Neurol. 2009. 66. (2). 184–190.
21. Nussbaum R.L., McInnes R.R., Willard H.F. Thompson and Thompson Genetics in Medicine. Philadelphia: Saunders, 2004
22. Orphan Drug Regulations 21 CFR Part 316. Federal Register 2013. 78. N113. http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/OrphanDrugAct/
23. Orphan medicinal product designation (SOP/H/3049). http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_-_SOP/2009/09/WC500002947.pdf
24. Procedure for orphan medicinal product designation. Guidance for sponsors (EMA/710915/2009 Rev. 11. 20 February 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/09/WC500003769.pdf
25. Rare diseases and orphan products. Accelerating research and development / Eds. M.J. Field, T.F. Boat. Washington: Natl. Academ. Press, 2010. http://thcc.or.th/ICD-10TM/ge70.htm.
26. Regulation (EC) N 141/2000 of the European parliament end of the council of 16 December 1999 on orphan medicinal products // Official J. Eur. Union. 2000. 18. (1). 1–5.
27. Regulation (EC) N 726/2004 of the European parliament end of the council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency // Official J. Eur. Union. 2004. 136. (1). 1–33.
28. Review of orphan designation at the time of granting/varying a marketing authorization (SOP/H/3190). http://www.ema.europa.eu/docs/en_GB/document_library/Standard_Operating_Procedure_- SOP/2009/09/WC500003013.pdf
29. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia // Orphanet J. Rare Dis. 2007. 2. (21). 1750–1772.
30. Smits P., Bolton A.D., Funari V. et al. Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210 // N. Engl. J. Med. 2010. 362. (3). 206–216.